Active Clinical Trials and Research Studies on EGIDs
Please click on the link to learn more details about the trial, its purpose, who may participate, locations, and phone numbers. Please seek advice from your medical teams about the clinical trials or studies you are interested in. The items are listed in date order & updated periodically:
ENGAGE – adults and adolescents who have EoG with or without EoD
Is eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD) affecting your daily life?
The below website link provides information about a clinical study, Engage, for adults and adolescents who have EoG with or without EoD. Currently, there is no suitable long-term treatment for EoG. Considering this gap in treatment, the Engage clinical research study aims to assess the safety and efficacy of a study drug in treating EoG in adults and adolescents.
Is eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD) affecting your daily life?
The below website link provides information about a clinical study, Engage, for adults and adolescents who have EoG with or without EoD. Currently, there is no suitable long-term treatment for EoG. Considering this gap in treatment, the Engage clinical research study aims to assess the safety and efficacy of a study drug in treating EoG in adults and adolescents.
PilOt Assessment To Find Evidence Of Gastric Motility Abnormalities In Eosinophilic Gastric Disorders" (OAT-FEED)
The trial is being conducted to learn whether there are problems with stomach emptying in patients with Eosinophilic gastritis. Participation may last up to 20 weeks.
EOE Trial & You
The CROSSING study for adults and adolescents with EoE
The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients between 12 and 80 years of age.
Flute 3 -Advancing Oral Treatment Options for People with Eosinophillic Esophagitis (EoE)
If you have difficulty swallowing or if food going down feels uncomfortable, you may have EoE. If you are diagnosed with EoE, you may be able to participate in a clinical trial called FLUTE 3 (FLUTicasone propionate in Eosinophilic esophagitis) assessing APT-1011. APT-1011 is an investigational tablet that is placed on the back of the tongue once a day at bedtime. After the tablet melts (in less than 30 seconds) it is swallowed to coat the esophagus. The clinical trial FLUTE 3, will evaluate if APT-1011 treats the inflammation causing your EoE symptoms.
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: – Placebo for Induction and Maintenance – CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance – CC-93538 360 mg SC once weekly for Induction and Maintenance
To check eligibility answer these few questions.
DESTINY study for adults with HES Expand
To check eligibility take this survey
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000 cells/ microliter (μL) during Screening. Historical HES flares are defined as documented HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy.
Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive either depemokimab or placebo while continuing their SoC HES therapy.
OCEAN study for adults with EGPA
A GSK clinical trial: This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Study in Pediatrics with HypEREosinophilic syndrome (SPHERE)
A GSK clinical trial: The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard-of-care (SoC) therapy.
Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab (MANDARA)
How to participate: NCT04157348
AstraZeneca
Study Start Date: November 2019
Contact: Clinic Location based on Location
A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) (NATRON)
How to participate: NCT04191304
Study Website: NATRON
AstraZeneca
Study Start Date: December 2019
Contact: visit Study Website
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
Study Start Date: June 2015
National Institute of Allergy and Infectious Diseases (NIAID)
How to Participate: NTC02523118
Esophageal String Test in Eosinophilic Esophagitis
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
Study Start Date: December 2005
Children’s Hospital Medical Center, Cincinnati
How to Participate: NTC00267501